Of note, SD lasting from 247 to 417 days was noted in patients with HCC (n = 2), renal cell carcinoma (n = 1), or GIST (n = 1) who had progressed following prior VEGF‐targeted, antiangiogenesis therapy. This evidence concerns the gene VEGFA and renal cell carcinoma.